Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Scilex Holding Co's 9-Day RSI or its related term are showing as below:
FRA:D8B0's 9-Day RSI is ranked better than 64.78% of 1045
companies
in the Drug Manufacturers industry
Industry Median: 47.8
vs FRA:D8B0: 40.91
Scilex Holding Co (FRA:D8B0) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Scilex Holding Co 9-Day RSI Related Terms
FRA:D8B0 vs MIRA, NSRX, MDCX: 9-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's 9-Day RSI falls into.
Scilex Holding Co (FRA:D8B0) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (FRA:D8B0) has a 9-Day RSI of 40.91 as of Jul. 22, 2026. According to the industry distribution chart, Scilex Holding Co ranks #368 out of 1045 companies in the Drug Manufacturers industry, placing it in the top 35.2%.
Is Scilex Holding Co's 9-Day RSI too high?
Scilex Holding Co's current 9-Day RSI is 40.91. The Drug Manufacturers industry median 9-Day RSI is 47.80. Scilex Holding Co's value of 40.91 is 14.4% below this industry median. Based on the distribution chart, Scilex Holding Co ranks #368 out of 1045 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Scilex Holding Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's 9-Day RSI compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #368 out of 1045 companies for 9-Day RSI. This puts Scilex Holding Co in the upper half of its industry. The industry median 9-Day RSI is 47.80. Scilex Holding Co's value of 40.91 is 14.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 47.80, based on 1,045 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scilex Holding Co's current 9-Day RSI of 40.91 is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 47.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current 9-Day RSI is 40.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (FRA:D8B0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.77, compared to a current price of €6.40 — trading 34.2% above its estimated fair value. The current 9-Day RSI is 40.91 and 14.4% below the Drug Manufacturers industry median of 47.80. Scilex Holding Co's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Scilex Holding Co (FRA:D8B0), the current 9-Day RSI is 40.91 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of €6.40 is trading 34.2% above its estimated GF Value™ of €4.77.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for FRA:D8B0:
9-Day RSI: 40.91
GF Value™: €4.77 vs. price of €6.40 (34.2% above fair value)
Industry Position: 14.4% below the Drug Manufacturers median (#368 of 1045)
No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score
Get the complete analysis for FRA:D8B0
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D8B0 has been successfully added to your 
